# ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

> **NCT06680661** · PHASE2 · RECRUITING · sponsor: **Leland Metheny** · enrollment: 20 (estimated)

## Conditions studied

- Acute Myelogenous Leukemia
- Acute Lymphatic Leukemia
- Chronic Myelogenous Leukemia
- Myelodysplastic Syndromes
- Myelodysplastic Syndrome Other
- Chronic Myelomonocytic Leukemia
- Lymphoma
- Hodgkin Lymphoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Thiotepa
- **RADIATION:** Total Body Irradiation
- **BIOLOGICAL:** Double Umbilical Cord Transplant
- **DRUG:** Tacrolimus
- **DRUG:** Mycophenolate Mofetil
- **DRUG:** Abatacept

## Key facts

- **NCT ID:** NCT06680661
- **Lead sponsor:** Leland Metheny
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-25
- **Primary completion:** 2027-10-29
- **Final completion:** 2028-10-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06680661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06680661, "ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT06680661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*